Lead Product(s): Anti-tau monoclonal antibody
Therapeutic Area: Neurology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Aprinoia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 16, 2020
The candidate was selected from APRINOIA’s proprietary antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes.